|
|
|
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps...
Developing human gene therapy products for cystic fibrosis and hemophilia B and DNA vaccinations The company creates proprietary PLASmin Complexes which are efficient non-viral vectors and REPLIsome vectors which allow...
Holy hemophilia - another drop in the hemorrhage of leaks. "Afghan minister accused of taking bribe" screams a dog-bites-man headline. Who's doing the accusing? Why, it's none other than "a U.S. official who is familiar with...
India's News.Net Wednesday 18th November, 2009 (IANS) A new genetically engineered treatment for hemophilia, a dreaded disease where blood doesn't clot, was launched here Wednesday by a private pharmaceutical company. Unlike...
What Doctor's Don't Tell You About Blood Transfusions Blood undoubtedly saves many lives each year but it also carries risks, some life threatening, that recipients are rarely informed of. Donated blood has saved the lives of...
The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps...
blog.taragana.com Adolor buys rights to Eli Lilly drug, plans studies on opioid bowel dysfunction (Mon Nov 16 01:49:39 2009 PST) [$drug_related(100%), $drugwar_propaganda(80%), $propaganda_theme2(80%), $propaganda_theme3(50%),...
When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research...
Record keeping is integral to home treatment for hemophilia. Identified problems with paper diaries include suboptimal compliance and questionable data validity and quality. The effects of an electronic data recording system,...
NEW YORK (AP) - Biotechnology manufacturer Talecris Biotherapeutics said Friday it will spend $268.7 million and get state and local incentives to expand a plant in Clayton, N.C. The facility makes protein therapies used to...
